DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its Q2 2021 financial results post-market on August 11, with a live conference call scheduled for August 12 at 7:00 AM CT. The call aims to provide updates on business developments and financial outcomes. DiaMedica focuses on innovative treatments for neurological disorders and kidney diseases, specifically advancing its lead candidate DM199 in clinical trials for acute ischemic stroke and chronic kidney disease.

Positive

• Advancing DM199 in Phase 2/3 REMEDY trial for acute ischemic stroke.
• Completing enrollment in REDUX Phase 2 trial for chronic kidney disease.

Negative

• None.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2021 financial results will be released after the markets close on Wednesday, August 11^th. DiaMedica will host a live conference call on Thursday, August 12^th at 7:00 AM Central Time to discuss its business update and financial results.

Conference Call details:

Date:	Thursday, August 12, 2021
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://event.on24.com/wcc/r/3192933/FBC5C2BE41E26E2C70F89B28EC5DB100
Dial In:	(844) 557-8483 (domestic)
	(825) 312-2381 (international)
Conference ID:	4148874

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 19, 2021, by dialing (800) 585-8367 (US Toll Free), (416) 621-4642 (International), and entering the replay passcode: 4148874.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Our lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, we are advancing DM199 in our REMEDY Phase 2/3 trial in the treatment of AIS and completing enrollment in our REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005185/en/

FAQ

When will DiaMedica Therapeutics announce their Q2 2021 financial results?

DiaMedica Therapeutics will announce their Q2 2021 financial results after the market closes on August 11, 2021.

What time is the DiaMedica conference call for Q2 2021 results?

The conference call for DiaMedica's Q2 2021 results is scheduled for August 12, 2021, at 7:00 AM CT.

How can I access the DiaMedica conference call?

You can access the DiaMedica conference call by dialing (844) 557-8483 for domestic or (825) 312-2381 for international calls, or by listening to the webcast available on their website.

What is the lead candidate of DiaMedica Therapeutics?

DiaMedica's lead candidate is DM199, aimed at treating acute ischemic stroke and chronic kidney disease.